Loading
MLLT3 (MLLT3 super elongation complex subunit) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma and Melanoma.
Chromatin reader component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. Specifically recognises and binds acylated histone H3, with a preference for histone H3 that is crotonylated. Crotonylation marks active promoters and enhancers and confers resistance to transcriptional repressors.
Open Targets scores its association with cancer at 0.50 (direct and indirect evidence; datatypes literature 0.98, animal model 0.38, genetic association 0.46, somatic mutation 0.65). IntOGen calls it a driver in 1 cohort (0 activating, 0 loss-of-function), covering Melanoma.
In plain words · MLLT3 (MLLT3 super elongation complex subunit) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma and Melanoma.
MLLT3 (MLLT3 super elongation complex subunit) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma and Melanoma.
Chromatin reader component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA.
No product in this corpus aims at MLLT3 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
First described 1993. Earliest sequence paper UniProt cites for the protein: Nakamura et al, Proc. Natl. Acad. Sci. U.S.A, 1993, "Genes on chromosomes 4, 9, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs". Source.
Sources: HGNC HGNC:7136 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P42568 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000171843 (association with cancer (MONDO_0004992) 0.50; per-cancer scores at or above 0.5: non-Hodgkin lymphoma 0.52, leukaemia 0.52 (GraphQL API, CC0)); IntOGen MLLT3 (driver in 1 cohort (Act 0, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Chromatin reader component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. Specifically recognises and binds acylated histone H3, with a preference for histone H3 that is crotonylated. Crotonylation marks active promoters and enhancers and confers resistance to transcriptional repressors. Recognises and binds histone H3 crotonylated at 'Lys-9' (H3K9cr), and with slightly lower affinity histone H3 crotonylated at 'Lys-18' (H3K18cr). Also recognises and binds histone H3 acetylated and butyrylated at 'Lys-9' (H3K9ac and H3K9bu, respectively), but with lower affinity than crotonylated histone H3. In the SEC complex, MLLT3 is required to recruit the complex to crotonylated histones. Location: Nucleus; Chromosome (UniProt). Locus 9p21.3 (HGNC).
Query for this target: (TITLE:"MLLT3" OR ABSTRACT:"MLLT3" OR TITLE:"MLLT3 super elongation complex subunit" OR ABSTRACT:"MLLT3 super elongation complex subunit" OR TITLE:"AF-9" OR ABSTRACT:"AF-9" OR TITLE:"AF9" OR ABSTRACT:"AF9" OR TITLE:"YEATS3" OR ABSTRACT:"YEATS3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MLLT3, not a curated reading list.
Shares Leukaemia (all types), IntOGen, Non-Hodgkin lymphoma (all types), Melanoma.
Shares Leukaemia (all types), IntOGen, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), IntOGen, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), IntOGen, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Melanoma, Open Targets Platform.
Shares Leukaemia (all types), IntOGen, Non-Hodgkin lymphoma (all types), Melanoma.
Shares Leukaemia (all types), IntOGen, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), IntOGen, Non-Hodgkin lymphoma (all types), Open Targets Platform.